Parkinson’s disease has historically relied on a clinical diagnosis built around characteristic motor features and supportive clinical criteria Emjreviews. However, clinicopathological studies indicate that diagnostic accuracies hover between 70% and 85%, with even lower accuracy rates observed during early disease stages and atypical parkinsonism Emjreviews. Developing and implementing precision disease-modifying therapies requires biomarkers that reflect the underlying biology rather than outward clinical phenotypes Emjreviews.
Shifting From Clinical Phenotype to Biological Diagnosis
This challenge extends across the broader landscape of neurodegenerative conditions. Disorders such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and Alzheimer’s disease can appear remarkably similar during their early stages Drugdiscoverynews. Meanwhile, pathology demonstrates that most neurodegenerative diseases are driven by the misfolding and aggregation of specific proteins spreading through the brain in distinct patterns Drugdiscoverynews.
Detecting Misfolded Alpha-Synuclein Through Seed Amplification Assays
To address these diagnostic limitations, researchers are turning to cerebrospinal fluid (CSF) testing via seed amplification assays (SAA) to detect misfolded alpha-synuclein (αSyn) Emjreviews. Unlike traditional biomarkers that capture downstream consequences of disease, αSyn–SAA amplifies and detects misfolded αSyn aggregates, which form the primary component of Lewy bodies and Lewy neurites characteristic of Parkinson’s disease and related synucleinopathies Emjreviews.
Russell Lebovitz of Amprion Diagnostics noted the expanding scope of the protein, stating, Initially, we assumed synuclein would be relevant in maybe a quarter of patients. What we’ve learned since is that it shows up in closer to 60 percent of people with neurodegenerative disease.
Drugdiscoverynews Furthermore, experimental and pathological evidence indicates that misfolded alpha-synuclein can interact with and potentially accelerate the aggregation of amyloid-beta and tau, helping to explain why mixed pathology is common Drugdiscoverynews.
Multicenter Study Findings and Early Detection Potential
Multicenter studies have reported sensitivity exceeding 85% to 90% for clinically diagnosed Parkinson’s disease, alongside high specificity among healthy controls and individuals with other neurodegenerative diseases Emjreviews. Particularly impactful initial findings from the Parkinson’s Progression Markers Initiative (PPMI) cohort demonstrated αSyn–SAA positivity in 87.7% of Parkinson’s participants and 86% of prodromal participants before any evidence of dopaminergic deficit Emjreviews. These results suggest that αSyn pathology detectable by SAA may precede neurodegeneration identified through conventional imaging Emjreviews.
Recent technological advances have also shown an ability to distinguish multiple system atrophy (MSA) from Parkinson’s disease and other synucleinopathies Emjreviews. This distinction represents an important clinical advance given the rapid progression and poorer prognosis associated with MSA Emjreviews, which manifests typically in the 6th life decade with an average life expectancy of 5 to 9 years after diagnosis Frontiersin.
Real-World Implementation and Regulatory Frameworks
While research cohorts have been well-characterised, routine neurology clinic patients frequently present with overlapping symptoms, vascular disease, medication effects, or uncertain diagnoses Emjreviews. Evidence also indicates that synuclein pathology frequently coexists with other neurodegenerative conditions like Alzheimer’s disease Emjreviews. As clinical adoption expands, performance across broader patient populations will further refine evidence-based clinical use guidelines Emjreviews.
Current testing relies primarily on cerebrospinal fluid, though continued advancements in blood- and skin-based assays could improve accessibility Emjreviews. In the United States, the test is offered to clinicians as a laboratory-developed test in compliance with Clinical Laboratory Improvement Amendments (CLIA) regulations through a centralised commercial laboratory Emjreviews. In Europe, implementation must comply with the European Union In Vitro Diagnostic Regulation (IVDR), which is also expected to occur initially through centralised reference laboratories operating under standardized workflows Emjreviews.
Keep reading